| Molecular Formula | C10H13NO4S2 |
| Molar Mass | 275.34 |
| Density | 1.4366 (rough estimate) |
| Melting Point | 236-237° |
| Boling Point | 549.1±60.0 °C(Predicted) |
| Appearance | neat |
| pKa | 9.71±0.20(Predicted) |
| Storage Condition | Sealed in dry,2-8°C |
| Refractive Index | 1.6800 (estimate) |
| In vivo study | Meticrane, a thiazide diuretic is highly ranked in the connectivity map (cMap) analysis, and it does not have any known anti-cancer or immune-stimulating effect. Co-treatment with Meticrane significantly enhances treatment efficacy of CTLA-4 blockade. |
| WGK Germany | 2 |
| RTECS | XK6360000 |
| 1mg | 5mg | 10mg | |
|---|---|---|---|
| 1 mM | 3.632 ml | 18.159 ml | 36.318 ml |
| 5 mM | 0.726 ml | 3.632 ml | 7.264 ml |
| 10 mM | 0.363 ml | 1.816 ml | 3.632 ml |
| 5 mM | 0.073 ml | 0.363 ml | 0.726 ml |
| biological activity | Meticrane is a diuretic that can inhibit the reabsorption of reabsorption ofsodiumandchlorideions in distal curved tubules. Meticrane can be used to treat essential hypertension. |
| target | Sodium and chloride ion |
| in vivo research | Meticrane, a thiazide diuretic is highly rank in the connectivity map (cMap) analysis, and it does not have any known anti-cancer or stimulating effect. Co-treatment with Meticrane significantly enhances treatment efficacy of CTLA-4 blockade. |
| EPA chemical information | Information provided by: ofmpub.epa.gov (external link) |